Lori Westendorf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lori Westendorf has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Hale
Seagen Inc., Bothell, Washington
55 shared publications - Roma Yumul
Seagen Inc., Bothell, Washington
55 shared publications - Peter D. Senter
Pfizer, Inc., Bothell, Washington
53 shared publications - Vivian H. Trang
Pfizer, Inc , New York, New York
53 shared publications - Abbie Wong
Pfizer, Inc., Bothell, Washington
52 shared publications - Alice P. Chin
Pfizer, Inc., Bothell, Washington
52 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
PF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- 24 August 2026
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- p. OF1-OF11
Open AccessPF-08046876, a Differentiated Integrin Beta-6 Antibody–Drug Conjugate Delivering a Potent Camptothecin Payload Optimized for Bystander Effect and Reduced Drug Efflux
Integrins represent a large family of cell surface receptors that exist as heterodimers with essential roles in key biological processes such as cellular adhesion, motility, and cytokinesis. Among them, integrin beta-6 (IB6), which exclusively dimerizes with integrin alpha-v, has emerged as a clinically relevant target due to its restricted expression in normal adult epithelial tissues and elevated levels in solid tumors. High expression of IB6 is correlated with poor prognosis across multiple solid tumor types. PF-08046876 is an investigational antibody–drug conjugate consisting of the anti-IB6 mAb conjugated to a camptothecin-class topoisomerase I (TOP1) inhibitor, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), using a traceless enzyme-cleavable glucuronide linker. The AMDCPT payload has been optimized for differentiation from other TOP1 inhibitors, with improved potency, enhanced bystander activity, and reduced susceptibility to multidrug resistance efflux mechanisms. PF-08046876 leverages the same antibody backbone from sigvotatug vedotin and binds IB6 without cross-reactivity to other alpha-v integrin complexes. In preclinical studies, PF-08046876 has demonstrated significant antitumor activity both in vitro and in vivo across multiple tumor models with IB6 expression, including non–small cell lung, head and neck squamous cell, urothelial, pancreatic, and esophageal carcinomas. These findings support further clinical development of PF-08046876 as a promising therapeutic candidate for the treatment of IB6-expressing solid tumors.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 3. MMP2 and MMP9 quantification from select tumor models.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
H-Scores for integrin beta-6 across different cancer types
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S3 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
H-Scores for integrin beta-6 across different cancer types
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 16 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 16. Production of proteases in culture by cancer cells is sufficient to activate SGN-CD47M to restore binding and function.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 16 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 16. Production of proteases in culture by cancer cells is sufficient to activate SGN-CD47M to restore binding and function.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Antitumor activity in cell line-derived xenograft models
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Antitumor activity in cell line-derived xenograft models
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 13. Assessment of the ability of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47, and a IgG1 isotype control antibody to induce direct apoptosis of THP1 cells, as assessed by flow cytometry of Annexin V cell surface expression.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 13. Assessment of the ability of hB6H12.3, SGN-CD47M, MMP-cleaved SGN-CD47, and a IgG1 isotype control antibody to induce direct apoptosis of THP1 cells, as assessed by flow cytometry of Annexin V cell surface expression.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 5 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 5. Pharmacokinetic parameters of gTAb in monkey plasma following a single IV dose of hB6H12.3 (1 mg/kg) or SGN-CD47M (10 or 20 mg/kg) as determined by non-compartmental analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 5 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Table 5. Pharmacokinetic parameters of gTAb in monkey plasma following a single IV dose of hB6H12.3 (1 mg/kg) or SGN-CD47M (10 or 20 mg/kg) as determined by non-compartmental analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 14 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 14. Induction of ADCC, assessed using FcγRIIIa-V158 Jurkat NFAT reporter cells incubated with CD47-expressing WIL2-S target cells and increasing concentrations of anti-CD47 antibodies or isotype control.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 14 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 14. Induction of ADCC, assessed using FcγRIIIa-V158 Jurkat NFAT reporter cells incubated with CD47-expressing WIL2-S target cells and increasing concentrations of anti-CD47 antibodies or isotype control.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 2 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Cell lines used in the characterization of SGN-B6A
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 2 from SGN-B6A: A New Vedotin Antibody–Drug Conjugate Directed to Integrin Beta-6 for Multiple Carcinoma Indications
Cell lines used in the characterization of SGN-B6A
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 19 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 19. Protease activity of select syngeneic and xenograft tumor models was assessed using an activatable cell-penetrating peptide (ACPP)2 bearing the -IPVSLRSG- cleavage sequenced used in Coil-MMP-mIAP301 and SGN-CD47M antibodies.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 19 from Preclinical Development of SGN-CD47M: Protease-Activated Antibody Technology Enables Selective Tumor Targeting of the Innate Immune Checkpoint Receptor CD47
Supplementary Figure 19. Protease activity of select syngeneic and xenograft tumor models was assessed using an activatable cell-penetrating peptide (ACPP)2 bearing the -IPVSLRSG- cleavage sequenced used in Coil-MMP-mIAP301 and SGN-CD47M antibodies.